READ MORE ABOUT APPLICATIONS
||
NEWS:

September 20 - 24, 2010

46th EASD Annual Meeting - Stockholm

European Association for the Study of DiabetesOral presentation:

  • "Urinary proteome analysis for diagnosis of diabetic nephropathy"
  • "Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology"


Poster presentation:

  • "Urinary proteomics for early diagnosis in DN"

FEATURED ARTICLES:

Nephrology

Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease.

MCP 2010 Jul |  Read more

Methodology

Comprehensive human urine standards for comparability and standardization in clinical proteome analysis.
Proteomics Clinical Applications 2010; 4:464-478

Methodology

Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease
Journal of Proteome Research 2009; 8(1): 268-281


Cardiovascular Disease

Evaluation of Urine Proteome Pattern Analysis for Its Potential To Reflect Coronary Artery Atherosclerosis in Symptomatic Patients
Journal of Proteome Research 2009, 8(1): 335-345

Oncology

Prediction of Muscle-invasive Bladder Cancer Using Urinary Proteomics
Clin Cancer Res. 2009 Aug 1;15(15):4935-43. Epub 2009 Jul

Protein Analysis for Clinical Diagnosis and Pharmaceutical Research

Mosaiques diagnostics provides highly innovative Clinical Proteomics services for academic institutions and pharmaceutical companies. Mosaiques revolutionary CE-MS technology (capillary electrophoresis coupled to mass spectrometry) helps to diagnose severe diseases at an early development stage, control efficacy of applied therapies in personalized medicine, examine efficacy of new drugs in preclinical (animal models) and clinical trials and to identify therapeutic targets.

The unique CE-MS technology displays peptides and proteins of body fluids. The generated pattern filed in a database provides a fast and authentic description of the individual health of an organism. Measurement of the proteome in combination with on-line database matching is the key to an all-in-one diagnosis for a wide spectrum of clinical applications.

DiaPat GmbH, a subsidiary of mosaiques diagnostics and therapeutics AG, markets successfully new diagnostic tests in Europe for Chronic Renal Diseases (including Diabetic Nephropathy), Bladder Cancer, Prostate Cancer, Coronary Artery Disease, Ureteropelvic Junction Obstruction in Neonates and for early detection of Graft-versus-Host Disease, based on the technology described.

  • RESEARCH & DEVELOPMENT
  • PUBLICATIONS
  • ABOUT MOSAIQUES
  • APPLICATIONS
  • Clinical Study